ArticleJournal of molecular histology2025
Impaired therapeutic efficacy of sleep-deprived bone marrow mesenchymal stem cells in the cerebellum of mouse cuprizone model of multiple sclerosis: stereological and motor behavioral evidence.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synthesis and Evaluation of the Effects of Nanoparticles of Atorvastatin and Atorvastatin on Cuprizone-Induced Demyelination: Modulation of the Nrf2/NF-kB Signaling Pathway.Iranian journal of pharmaceutical research : IJPRArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Multiple sclerosis (MS) leads to histological changes, which in turn result in functional deficits. Studies have reported that bone marrow mesenchymal stem cells (BMSCs) have therapeutic benefits in MS. In addition, sleep deprivation affects therapeutic potential of BMSCs. This research aimed to evaluate the effects of BMSCs compared to sleep-deprived BMSCs (SD-BMSCs) on the motor behavior and histological recovery in MS. The mice were divided into four groups receiving cuprizone for five weeks, with or without intranasal administration of cells (BMSCs or SD-BMSCs) after five weeks. After a two-week recovery period, balance beam and pole tests were performed to assess motor performance, followed by estimation of histological parameters using stereological methods. Mice that received BMSCs scored significantly better than the SD-BMSC group in balance beam and pole tests (P < 0.05). The total cerebellar volume, cortex, and white matter volumes, as well as the total number of Purkinje cells in mice that received BMSCs, were significantly higher compared to those in the SD-BMSC group (P < 0.05). Intranasal administration of BMSCs leads to significantly improved motor behavior and histological regeneration of the cerebellum, including cortex and white matter as well as Purkinje cells compared to SD-BMSCs in a cuprizone model of multiple sclerosis.
Indexed as
Identifiers
40616615What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.